Key result
Group B coxsackievirus drives myocarditis progression across three distinct immunologic stages toward dilated cardiomyopathy.
Why the study?
Viral myocarditis is a primary cause of dilated cardiomyopathy, and current chronic myocarditis therapies remain unsatisfactory.
This review provides a comprehensive overview of the innate and adaptive immune mechanisms involved in the development of CVB3-induced viral myocarditis.
Answers are grounded in this paper and cite their sources.
Suggests intervention windows in CVB3 myocarditis; leaves open clinical translation from experimental models.
Viral myocarditis is known to be a primary cause of dilated cardiomyopathy (DCM) that can lead to heart failure and sudden cardiac death and is invariably caused by myocardial viral infection following active inflammatory destruction of the myocardium. Although acute viral myocarditis frequently recovers on its own, current chronic myocarditis therapies are unsatisfactory, where the persistence of viral or immunological insults to the heart may play a role. Cellular and mouse experimental models that utilized the most prevalent Coxsackievirus group B type 3 (CVB3) virus infection causing myocarditis have illustrated the pathophysiology of viral myocarditis. In this review, immunological insights into the different stages of development of viral myocarditis were discussed, concentrating on the mechanisms of innate and adaptive immunity in the development of CVB3-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a review in Viral myocarditis. Group B coxsackievirus infection drives viral myocarditis progression through three stages involving innate immune activation, autoimmune responses, and potentially leading to dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: